MARI.VI Marinomed Biotech AG

Healthcare Biotechnology Vienna Exchange
4.00 EUR
Close of Oct 30, 2026
2.20 20.70
Market cap
EUR 8.00M
P/E
0.4x
P/B
597.26x
ROE
-
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is MARI.VI undervalued?

Graham number

The Graham number of Marinomed Biotech AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Marinomed Biotech AG fundamental analysis

6 of 22 checks passed

ROE 0/2

ROE cannot be calculated: equity is negative or not reported.

ROA 1/1

Return on assets (257.1%) is above the industry median (-19.8%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (195.9%) is above the industry median (3.8%).

Revenue Growth 0/2

Revenue shrank 11.9% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 37.4x against interest expense, well covered.

PE vs Market 1/1

PE (0.4x) is below the market median (18.5x).

PE vs Industry 1/1

PE (0.4x) is below the industry median (18.6x).

PBV 0/1

Price to book (597.3x) is above the industry median (3.1x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 236.5, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Marinomed Biotech AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Marinomed Biotech AG

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation developmen…

Full company profile